{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:13:19Z","timestamp":1750219999273,"version":"3.41.0"},"publisher-location":"New York, NY, USA","reference-count":81,"publisher":"ACM","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.acm.org\/publications\/policies\/copyright_policy#Background"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902933, 81802676"],"award-info":[{"award-number":["81902933, 81802676"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dl.acm.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,28]]},"DOI":"10.1145\/3571532.3571535","type":"proceedings-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T23:10:33Z","timestamp":1675725033000},"page":"16-29","update-policy":"https:\/\/doi.org\/10.1145\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Network Analysis Identifies Potential Small-Molecule Drugs Sensitizing Triple-Negative Breast Cancer to Tamoxifen"],"prefix":"10.1145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1008-9283","authenticated-orcid":false,"given":"Mengying","family":"Zhou","sequence":"first","affiliation":[{"name":"Wuhan University of Science and Technology, Institute of Biology and Medicine, College of Life and Health Sciences, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8067-4851","authenticated-orcid":false,"given":"Xing Hua","family":"Liao","sequence":"additional","affiliation":[{"name":"Wuhan University of Science and Technology, Institute of Biology and Medicine, College of Life and Health Sciences, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"320","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"#cr-split#-e_1_3_2_1_1_1.1","doi-asserted-by":"crossref","unstructured":"Koboldt DC Fulton RS McLellan MD Schmidt H Kalicki-Veizer J McMichael JF Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70. https:\/\/doi.org\/10.1038\/nature11412. 10.1038\/nature11412","DOI":"10.1038\/nature11412"},{"key":"#cr-split#-e_1_3_2_1_1_1.2","doi-asserted-by":"crossref","unstructured":"Koboldt DC Fulton RS McLellan MD Schmidt H Kalicki-Veizer J McMichael JF Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70. https:\/\/doi.org\/10.1038\/nature11412.","DOI":"10.1038\/nature11412"},{"key":"e_1_3_2_1_2_1","first-page":"249","volume":"2021","author":"Nagayama A","unstructured":"Nagayama A , Vidula N , Bardia A. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates. Oncology 2021 : 249 \u2013 254 . https:\/\/doi.org\/10.46883\/ONC.2021.3505.0249. 10.46883\/ONC.2021.3505.0249 Nagayama A, Vidula N, Bardia A. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates. Oncology 2021:249\u201354. https:\/\/doi.org\/10.46883\/ONC.2021.3505.0249.","journal-title":"Bardia A. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates. Oncology"},{"key":"#cr-split#-e_1_3_2_1_3_1.1","doi-asserted-by":"crossref","unstructured":"Anders CK Carey LA. Biology Metastatic Patterns and Treatment of Patients with Triple-Negative Breast Cancer. Clin Breast Cancer 2009;9:S73-81. https:\/\/doi.org\/10.3816\/CBC.2009.s.008. 10.3816\/CBC.2009.s.008","DOI":"10.3816\/CBC.2009.s.008"},{"key":"#cr-split#-e_1_3_2_1_3_1.2","doi-asserted-by":"crossref","unstructured":"Anders CK Carey LA. Biology Metastatic Patterns and Treatment of Patients with Triple-Negative Breast Cancer. Clin Breast Cancer 2009;9:S73-81. https:\/\/doi.org\/10.3816\/CBC.2009.s.008.","DOI":"10.3816\/CBC.2009.s.008"},{"key":"#cr-split#-e_1_3_2_1_4_1.1","doi-asserted-by":"crossref","unstructured":"De Laurentiis M Cianniello D Caputo R Stanzione B Arpino G Cinieri S Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 2010;36:S80-6. https:\/\/doi.org\/10.1016\/S0305-7372(10)70025-6. 10.1016\/S0305-7372(10)70025-6","DOI":"10.1016\/S0305-7372(10)70025-6"},{"key":"#cr-split#-e_1_3_2_1_4_1.2","doi-asserted-by":"crossref","unstructured":"De Laurentiis M Cianniello D Caputo R Stanzione B Arpino G Cinieri S Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 2010;36:S80-6. https:\/\/doi.org\/10.1016\/S0305-7372(10)70025-6.","DOI":"10.1016\/S0305-7372(10)70025-6"},{"key":"#cr-split#-e_1_3_2_1_5_1.1","doi-asserted-by":"crossref","unstructured":"Wang C Vegna S Jin H Benedict B Lieftink C Ramirez C Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 2019;574:268-72. https:\/\/doi.org\/10.1038\/s41586-019-1607-3. 10.1038\/s41586-019-1607-3","DOI":"10.1038\/s41586-019-1607-3"},{"key":"#cr-split#-e_1_3_2_1_5_1.2","doi-asserted-by":"crossref","unstructured":"Wang C Vegna S Jin H Benedict B Lieftink C Ramirez C Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 2019;574:268-72. https:\/\/doi.org\/10.1038\/s41586-019-1607-3.","DOI":"10.1038\/s41586-019-1607-3"},{"key":"#cr-split#-e_1_3_2_1_6_1.1","doi-asserted-by":"crossref","unstructured":"Sarkar S Ghosh A Banerjee S Maity G Das A Larson MA CCN5\/WISP-2 restores ER-\u221d in normal and neoplastic breast cells and sensitizes triple negative breast cancer cells to tamoxifen. Oncogenesis 2017;6:e340-e340. https:\/\/doi.org\/10.1038\/oncsis.2017.43. 10.1038\/oncsis.2017.43","DOI":"10.1038\/oncsis.2017.43"},{"key":"#cr-split#-e_1_3_2_1_6_1.2","doi-asserted-by":"crossref","unstructured":"Sarkar S Ghosh A Banerjee S Maity G Das A Larson MA CCN5\/WISP-2 restores ER-\u221d in normal and neoplastic breast cells and sensitizes triple negative breast cancer cells to tamoxifen. Oncogenesis 2017;6:e340-e340. https:\/\/doi.org\/10.1038\/oncsis.2017.43.","DOI":"10.1038\/oncsis.2017.43"},{"key":"#cr-split#-e_1_3_2_1_7_1.1","doi-asserted-by":"crossref","unstructured":"Anbalagan M Sheng M Fleischer B Zhang Y Gao Y Hoang V Dual Src kinase\/pretubulin inhibitor KX-01 sensitizes ER\u03b1-negative breast cancers to tamoxifen through ER\u03b1 reexpression. Mol Cancer Res 2017;15:1491-502. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0297-T. 10.1158\/1541-7786.MCR-16-0297-T","DOI":"10.1158\/1541-7786.MCR-16-0297-T"},{"key":"#cr-split#-e_1_3_2_1_7_1.2","doi-asserted-by":"crossref","unstructured":"Anbalagan M Sheng M Fleischer B Zhang Y Gao Y Hoang V Dual Src kinase\/pretubulin inhibitor KX-01 sensitizes ER\u03b1-negative breast cancers to tamoxifen through ER\u03b1 reexpression. Mol Cancer Res 2017;15:1491-502. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0297-T.","DOI":"10.1158\/1541-7786.MCR-16-0297-T"},{"key":"#cr-split#-e_1_3_2_1_8_1.1","doi-asserted-by":"crossref","unstructured":"Fan M Chen J Gao J Xue W Wang Y Li W Triggering a switch from basal- to luminal-like breast cancer subtype by the small-molecule diptoindonesin G via induction of GABARAPL1. Cell Death Dis 2020;11:635. https:\/\/doi.org\/10.1038\/s41419-020-02878-z. 10.1038\/s41419-020-02878-z","DOI":"10.1038\/s41419-020-02878-z"},{"key":"#cr-split#-e_1_3_2_1_8_1.2","doi-asserted-by":"crossref","unstructured":"Fan M Chen J Gao J Xue W Wang Y Li W Triggering a switch from basal- to luminal-like breast cancer subtype by the small-molecule diptoindonesin G via induction of GABARAPL1. Cell Death Dis 2020;11:635. https:\/\/doi.org\/10.1038\/s41419-020-02878-z.","DOI":"10.1038\/s41419-020-02878-z"},{"key":"#cr-split#-e_1_3_2_1_9_1.1","doi-asserted-by":"crossref","unstructured":"Ma W Sun J Xu J Luo Z Diao D Zhang Z Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier. Theranostics 2020;10:2463-78. https:\/\/doi.org\/10.7150\/thno.38973. 10.7150\/thno.38973","DOI":"10.7150\/thno.38973"},{"key":"#cr-split#-e_1_3_2_1_9_1.2","doi-asserted-by":"crossref","unstructured":"Ma W Sun J Xu J Luo Z Diao D Zhang Z Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier. Theranostics 2020;10:2463-78. https:\/\/doi.org\/10.7150\/thno.38973.","DOI":"10.7150\/thno.38973"},{"key":"#cr-split#-e_1_3_2_1_10_1.1","doi-asserted-by":"crossref","unstructured":"Xu T Wang Z Dong M Wu D Liao S Li X. Chloride intracellular channel protein 2: prognostic marker and correlation with PD-1\/PD-L1 in breast cancer. Aging (Albany NY) 2020;12:17305-27. https:\/\/doi.org\/10.18632\/aging.103712. 10.18632\/aging.103712","DOI":"10.18632\/aging.103712"},{"key":"#cr-split#-e_1_3_2_1_10_1.2","doi-asserted-by":"crossref","unstructured":"Xu T Wang Z Dong M Wu D Liao S Li X. Chloride intracellular channel protein 2: prognostic marker and correlation with PD-1\/PD-L1 in breast cancer. Aging (Albany NY) 2020;12:17305-27. https:\/\/doi.org\/10.18632\/aging.103712.","DOI":"10.18632\/aging.103712"},{"key":"#cr-split#-e_1_3_2_1_11_1.1","doi-asserted-by":"crossref","unstructured":"Langfelder P Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008;9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559. 10.1186\/1471-2105-9-559","DOI":"10.1186\/1471-2105-9-559"},{"key":"#cr-split#-e_1_3_2_1_11_1.2","doi-asserted-by":"crossref","unstructured":"Langfelder P Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008;9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559.","DOI":"10.1186\/1471-2105-9-559"},{"key":"#cr-split#-e_1_3_2_1_12_1.1","doi-asserted-by":"crossref","unstructured":"Zhang Y Tseng JT-C Lien I-C Li F Wu W Li H. mRNAsi Index: Machine Learning in Mining Lung Adenocarcinoma Stem Cell Biomarkers. Genes (Basel) 2020;11:257. https:\/\/doi.org\/10.3390\/genes11030257. 10.3390\/genes11030257","DOI":"10.3390\/genes11030257"},{"key":"#cr-split#-e_1_3_2_1_12_1.2","doi-asserted-by":"crossref","unstructured":"Zhang Y Tseng JT-C Lien I-C Li F Wu W Li H. mRNAsi Index: Machine Learning in Mining Lung Adenocarcinoma Stem Cell Biomarkers. Genes (Basel) 2020;11:257. https:\/\/doi.org\/10.3390\/genes11030257.","DOI":"10.3390\/genes11030257"},{"key":"#cr-split#-e_1_3_2_1_13_1.1","doi-asserted-by":"crossref","unstructured":"Szklarczyk D Gable AL Lyon D Junge A Wyder S Huerta-Cepas J STRING v11: protein-protein association networks with increased coverage supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019;47:D607-13. https:\/\/doi.org\/10.1093\/nar\/gky1131. 10.1093\/nar","DOI":"10.1093\/nar\/gky1131"},{"key":"#cr-split#-e_1_3_2_1_13_1.2","doi-asserted-by":"crossref","unstructured":"Szklarczyk D Gable AL Lyon D Junge A Wyder S Huerta-Cepas J STRING v11: protein-protein association networks with increased coverage supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019;47:D607-13. https:\/\/doi.org\/10.1093\/nar\/gky1131.","DOI":"10.1093\/nar\/gky1131"},{"key":"#cr-split#-e_1_3_2_1_14_1.1","doi-asserted-by":"crossref","unstructured":"Sun CC Li SJ Hu W Zhang J Zhou Q Liu C Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer. Mol Ther 2019;27:1153-65. https:\/\/doi.org\/10.1016\/j.ymthe.2019.03.019. 10.1016\/j.ymthe.2019.03.019","DOI":"10.1016\/j.ymthe.2019.03.019"},{"key":"#cr-split#-e_1_3_2_1_14_1.2","doi-asserted-by":"crossref","unstructured":"Sun CC Li SJ Hu W Zhang J Zhou Q Liu C Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer. Mol Ther 2019;27:1153-65. https:\/\/doi.org\/10.1016\/j.ymthe.2019.03.019.","DOI":"10.1016\/j.ymthe.2019.03.019"},{"key":"#cr-split#-e_1_3_2_1_15_1.1","doi-asserted-by":"crossref","unstructured":"Musa A Ghoraie LS Zhang SD Glazko G Yli-Harja O Dehmer M A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinform 2018;19:506-23. https:\/\/doi.org\/10.1093\/bib\/bbw112. 10.1093\/bib","DOI":"10.1093\/bib\/bbw112"},{"key":"#cr-split#-e_1_3_2_1_15_1.2","doi-asserted-by":"crossref","unstructured":"Musa A Ghoraie LS Zhang SD Glazko G Yli-Harja O Dehmer M A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinform 2018;19:506-23. https:\/\/doi.org\/10.1093\/bib\/bbw112.","DOI":"10.1093\/bib\/bbw112"},{"key":"#cr-split#-e_1_3_2_1_16_1.1","doi-asserted-by":"crossref","unstructured":"Irham LM Wong HS-C Chou W-H Adikusuma W Mugiyanto E Huang W-C Integration of genetic variants and gene network for drug repurposing in colorectal cancer. Pharmacol Res 2020;161:105203. https:\/\/doi.org\/10.1016\/j.phrs.2020.105203. 10.1016\/j.phrs.2020.105203","DOI":"10.1016\/j.phrs.2020.105203"},{"key":"#cr-split#-e_1_3_2_1_16_1.2","doi-asserted-by":"crossref","unstructured":"Irham LM Wong HS-C Chou W-H Adikusuma W Mugiyanto E Huang W-C Integration of genetic variants and gene network for drug repurposing in colorectal cancer. Pharmacol Res 2020;161:105203. https:\/\/doi.org\/10.1016\/j.phrs.2020.105203.","DOI":"10.1016\/j.phrs.2020.105203"},{"key":"e_1_3_2_1_17_1","first-page":"000","volume":"1","author":"Subramanian A","year":"2017","unstructured":"Subramanian A , Narayan R , Corsello SM , Peck DD , Natoli TE , Lu X, A Next Generation Connectivity Map : L100 0 Platform and the First 1 , 000 ,000 Profiles. Cell 2017 ;171:1437-1452.e17. https:\/\/doi.org\/10.1016\/j.cell.2017.10.049. 10.1016\/j.cell.2017.10.049 Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell 2017;171:1437-1452.e17. https:\/\/doi.org\/10.1016\/j.cell.2017.10.049.","journal-title":"Platform and the First"},{"key":"#cr-split#-e_1_3_2_1_18_1.1","doi-asserted-by":"crossref","unstructured":"Huang Y Wu H Li X. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer. Cancer Cell Int 2020;20:1-14. https:\/\/doi.org\/10.1186\/s12935-020-01597-x. 10.1186\/s12935-020-01597-x","DOI":"10.1186\/s12935-020-01597-x"},{"key":"#cr-split#-e_1_3_2_1_18_1.2","doi-asserted-by":"crossref","unstructured":"Huang Y Wu H Li X. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer. Cancer Cell Int 2020;20:1-14. https:\/\/doi.org\/10.1186\/s12935-020-01597-x.","DOI":"10.1186\/s12935-020-01597-x"},{"key":"#cr-split#-e_1_3_2_1_19_1.1","doi-asserted-by":"crossref","unstructured":"Chou T-C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Res 2010;70:440-6. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947. 10.1158\/0008-5472.CAN-09-1947","DOI":"10.1158\/0008-5472.CAN-09-1947"},{"key":"#cr-split#-e_1_3_2_1_19_1.2","doi-asserted-by":"crossref","unstructured":"Chou T-C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Res 2010;70:440-6. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947.","DOI":"10.1158\/0008-5472.CAN-09-1947"},{"key":"#cr-split#-e_1_3_2_1_20_1.1","doi-asserted-by":"crossref","unstructured":"Di Desidero T Orlandi P Gentile D Bocci G. Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells. Front Oncol 2019;9:1-9. https:\/\/doi.org\/10.3389\/fonc.2019.01202. 10.3389\/fonc.2019.01202","DOI":"10.3389\/fonc.2019.01202"},{"key":"#cr-split#-e_1_3_2_1_20_1.2","doi-asserted-by":"crossref","unstructured":"Di Desidero T Orlandi P Gentile D Bocci G. Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells. Front Oncol 2019;9:1-9. https:\/\/doi.org\/10.3389\/fonc.2019.01202.","DOI":"10.3389\/fonc.2019.01202"},{"key":"#cr-split#-e_1_3_2_1_21_1.1","doi-asserted-by":"crossref","unstructured":"Livak KJ Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods 2001;25:402-8. https:\/\/doi.org\/10.1006\/meth.2001.1262. 10.1006\/meth.2001.1262","DOI":"10.1006\/meth.2001.1262"},{"key":"#cr-split#-e_1_3_2_1_21_1.2","doi-asserted-by":"crossref","unstructured":"Livak KJ Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods 2001;25:402-8. https:\/\/doi.org\/10.1006\/meth.2001.1262.","DOI":"10.1006\/meth.2001.1262"},{"key":"#cr-split#-e_1_3_2_1_22_1.1","doi-asserted-by":"crossref","unstructured":"Xu T Zhang R Dong M Zhang Z Li H Zhan C Osteoglycin (OGN) Inhibits Cell Proliferation and Invasiveness in Breast Cancer via PI3K\/Akt\/mTOR Signaling Pathway. Onco Targets Ther 2019;Volume 12:10639-50. https:\/\/doi.org\/10.2147\/OTT.S222967. 10.2147\/OTT.S222967","DOI":"10.2147\/OTT.S222967"},{"key":"#cr-split#-e_1_3_2_1_22_1.2","doi-asserted-by":"crossref","unstructured":"Xu T Zhang R Dong M Zhang Z Li H Zhan C Osteoglycin (OGN) Inhibits Cell Proliferation and Invasiveness in Breast Cancer via PI3K\/Akt\/mTOR Signaling Pathway. Onco Targets Ther 2019;Volume 12:10639-50. https:\/\/doi.org\/10.2147\/OTT.S222967.","DOI":"10.2147\/OTT.S222967"},{"key":"#cr-split#-e_1_3_2_1_23_1.1","doi-asserted-by":"crossref","unstructured":"Soltani A Torki S Ghahfarokhi MS Jami MS Ghatrehsamani M. Targeting the phosphoinositide 3-kinase\/AKT pathways by small molecules and natural compounds as a therapeutic approach for breast cancer cells. Mol Biol Rep 2019;46:4809-16. https:\/\/doi.org\/10.1007\/s11033-019-04929-x. 10.1007\/s11033-019-04929-x","DOI":"10.1007\/s11033-019-04929-x"},{"key":"#cr-split#-e_1_3_2_1_23_1.2","doi-asserted-by":"crossref","unstructured":"Soltani A Torki S Ghahfarokhi MS Jami MS Ghatrehsamani M. Targeting the phosphoinositide 3-kinase\/AKT pathways by small molecules and natural compounds as a therapeutic approach for breast cancer cells. Mol Biol Rep 2019;46:4809-16. https:\/\/doi.org\/10.1007\/s11033-019-04929-x.","DOI":"10.1007\/s11033-019-04929-x"},{"key":"#cr-split#-e_1_3_2_1_24_1.1","doi-asserted-by":"crossref","unstructured":"Lee SY Song MY Kim D Park C Park DK Kim DG A proteotranscriptomic-based computational drug-repositioning method for Alzheimer's disease. Front Pharmacol 2020;10:1-11. https:\/\/doi.org\/10.3389\/fphar.2019.01653. 10.3389\/fphar.2019.01653","DOI":"10.3389\/fphar.2019.01653"},{"key":"#cr-split#-e_1_3_2_1_24_1.2","doi-asserted-by":"crossref","unstructured":"Lee SY Song MY Kim D Park C Park DK Kim DG A proteotranscriptomic-based computational drug-repositioning method for Alzheimer's disease. Front Pharmacol 2020;10:1-11. https:\/\/doi.org\/10.3389\/fphar.2019.01653.","DOI":"10.3389\/fphar.2019.01653"},{"key":"#cr-split#-e_1_3_2_1_25_1.1","doi-asserted-by":"crossref","unstructured":"Hsieh Y-Y Chou C-J Lo H-L Yang P-M. Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer. Cell Death Discov 2016;2:16027. https:\/\/doi.org\/10.1038\/cddiscovery.2016.27. 10.1038\/cddiscovery.2016.27","DOI":"10.1038\/cddiscovery.2016.27"},{"key":"#cr-split#-e_1_3_2_1_25_1.2","doi-asserted-by":"crossref","unstructured":"Hsieh Y-Y Chou C-J Lo H-L Yang P-M. Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer. Cell Death Discov 2016;2:16027. https:\/\/doi.org\/10.1038\/cddiscovery.2016.27.","DOI":"10.1038\/cddiscovery.2016.27"},{"key":"#cr-split#-e_1_3_2_1_26_1.1","doi-asserted-by":"crossref","unstructured":"Dong F Guo W Zhang L Wu S Teraishi F Davis JJ Downregulation of XIAP and induction of apoptosis by the synthetic cyclin-dependent kinase inhibitor GW8510 in non-small cell lung cancer cells. Cancer Biol Ther 2006;5:165-70. https:\/\/doi.org\/10.4161\/cbt.5.2.2316. 10.4161\/cbt.5.2.2316","DOI":"10.4161\/cbt.5.2.2316"},{"key":"#cr-split#-e_1_3_2_1_26_1.2","doi-asserted-by":"crossref","unstructured":"Dong F Guo W Zhang L Wu S Teraishi F Davis JJ Downregulation of XIAP and induction of apoptosis by the synthetic cyclin-dependent kinase inhibitor GW8510 in non-small cell lung cancer cells. Cancer Biol Ther 2006;5:165-70. https:\/\/doi.org\/10.4161\/cbt.5.2.2316.","DOI":"10.4161\/cbt.5.2.2316"},{"key":"#cr-split#-e_1_3_2_1_27_1.1","doi-asserted-by":"crossref","unstructured":"Lee K-L Kuo Y-C Ho Y-S Huang Y-H. Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. Cancers (Basel) 2019;11:1334. https:\/\/doi.org\/10.3390\/cancers11091334. 10.3390\/cancers11091334","DOI":"10.3390\/cancers11091334"},{"key":"#cr-split#-e_1_3_2_1_27_1.2","doi-asserted-by":"crossref","unstructured":"Lee K-L Kuo Y-C Ho Y-S Huang Y-H. Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. Cancers (Basel) 2019;11:1334. https:\/\/doi.org\/10.3390\/cancers11091334.","DOI":"10.3390\/cancers11091334"},{"key":"#cr-split#-e_1_3_2_1_28_1.1","doi-asserted-by":"crossref","unstructured":"Bhargava R Beriwal S McManus K Dabbs DJ. CK5 Is More Sensitive Than CK5\/6 in Identifying the \"Basal-like\" Phenotype of Breast Carcinoma. Am J Clin Pathol 2008;130:724-30. https:\/\/doi.org\/10.1309\/AJCP3KFF1LTYWQIY. 10.1309\/AJCP3KFF1LTYWQIY","DOI":"10.1309\/AJCP3KFF1LTYWQIY"},{"key":"#cr-split#-e_1_3_2_1_28_1.2","doi-asserted-by":"crossref","unstructured":"Bhargava R Beriwal S McManus K Dabbs DJ. CK5 Is More Sensitive Than CK5\/6 in Identifying the \"Basal-like\" Phenotype of Breast Carcinoma. Am J Clin Pathol 2008;130:724-30. https:\/\/doi.org\/10.1309\/AJCP3KFF1LTYWQIY.","DOI":"10.1309\/AJCP3KFF1LTYWQIY"},{"key":"#cr-split#-e_1_3_2_1_29_1.1","doi-asserted-by":"crossref","unstructured":"Laakso M Loman N Borg \u00c5 Isola J. Cytokeratin 5\/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005;18:1321-8. https:\/\/doi.org\/10.1038\/modpathol.3800456. 10.1038\/modpathol.3800456","DOI":"10.1038\/modpathol.3800456"},{"key":"#cr-split#-e_1_3_2_1_29_1.2","doi-asserted-by":"crossref","unstructured":"Laakso M Loman N Borg \u00c5 Isola J. Cytokeratin 5\/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005;18:1321-8. https:\/\/doi.org\/10.1038\/modpathol.3800456.","DOI":"10.1038\/modpathol.3800456"},{"key":"#cr-split#-e_1_3_2_1_30_1.1","doi-asserted-by":"crossref","unstructured":"Gong S Li Q Jeter CR Fan Q Tang DG Liu B. Regulation of NANOG in cancer cells. Mol Carcinog 2015;54:679-87. https:\/\/doi.org\/10.1002\/mc.22340. 10.1002\/mc.22340","DOI":"10.1002\/mc.22340"},{"key":"#cr-split#-e_1_3_2_1_30_1.2","doi-asserted-by":"crossref","unstructured":"Gong S Li Q Jeter CR Fan Q Tang DG Liu B. Regulation of NANOG in cancer cells. Mol Carcinog 2015;54:679-87. https:\/\/doi.org\/10.1002\/mc.22340.","DOI":"10.1002\/mc.22340"},{"key":"#cr-split#-e_1_3_2_1_31_1.1","doi-asserted-by":"crossref","unstructured":"Holding AN Cullen AE Markowetz F. Genome-wide Estrogen Receptor-\u03b1 activation is sustained not cyclical. Elife 2018;7. https:\/\/doi.org\/10.7554\/eLife.40854. 10.7554\/eLife.40854","DOI":"10.7554\/eLife.40854"},{"key":"#cr-split#-e_1_3_2_1_31_1.2","doi-asserted-by":"crossref","unstructured":"Holding AN Cullen AE Markowetz F. Genome-wide Estrogen Receptor-\u03b1 activation is sustained not cyclical. Elife 2018;7. https:\/\/doi.org\/10.7554\/eLife.40854.","DOI":"10.7554\/eLife.40854"},{"key":"#cr-split#-e_1_3_2_1_32_1.1","doi-asserted-by":"crossref","unstructured":"Hurtado A Holmes KA Ross-Innes CS Schmidt D Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011;43:27-33. https:\/\/doi.org\/10.1038\/ng.730. 10.1038\/ng.730","DOI":"10.1038\/ng.730"},{"key":"#cr-split#-e_1_3_2_1_32_1.2","doi-asserted-by":"crossref","unstructured":"Hurtado A Holmes KA Ross-Innes CS Schmidt D Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011;43:27-33. https:\/\/doi.org\/10.1038\/ng.730.","DOI":"10.1038\/ng.730"},{"key":"#cr-split#-e_1_3_2_1_33_1.1","doi-asserted-by":"crossref","unstructured":"Davis ST. Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors. Science (80- ) 2001;291:134-7. https:\/\/doi.org\/10.1126\/science.291.5501.134. 10.1126\/science.291.5501.134","DOI":"10.1126\/science.291.5501.134"},{"key":"#cr-split#-e_1_3_2_1_33_1.2","doi-asserted-by":"crossref","unstructured":"Davis ST. Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors. Science (80- ) 2001;291:134-7. https:\/\/doi.org\/10.1126\/science.291.5501.134.","DOI":"10.1126\/science.291.5501.134"},{"key":"e_1_3_2_1_34_1","volume-title":"Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: Identification of 3","author":"Johnson K","year":"2005","unstructured":"Johnson K , Liu L , Majdzadeh N , Chavez C , Chin PC , Morrison B , Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: Identification of 3 \u2019 substituted indolones as a scaffold for the development of neuroprotective drugs. J Neurochem 2005 ;93:538\u201348. https:\/\/doi.org\/10.1111\/j.1471-4159.2004.03004.x. 10.1111\/j.1471-4159.2004.03004.x Johnson K, Liu L, Majdzadeh N, Chavez C, Chin PC, Morrison B, Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: Identification of 3\u2019 substituted indolones as a scaffold for the development of neuroprotective drugs. J Neurochem 2005;93:538\u201348. https:\/\/doi.org\/10.1111\/j.1471-4159.2004.03004.x."},{"key":"#cr-split#-e_1_3_2_1_35_1.1","doi-asserted-by":"crossref","unstructured":"Wimalasena NK Le VQ Wimalasena K Schreiber SL Karmacharya R. Gene Expression-Based Screen for Parkinson's Disease Identifies GW8510 as a Neuroprotective Agent. ACS Chem Neurosci 2016;7:857-63. https:\/\/doi.org\/10.1021\/acschemneuro.6b00076. 10.1021\/acschemneuro.6b00076","DOI":"10.1021\/acschemneuro.6b00076"},{"key":"#cr-split#-e_1_3_2_1_35_1.2","doi-asserted-by":"crossref","unstructured":"Wimalasena NK Le VQ Wimalasena K Schreiber SL Karmacharya R. Gene Expression-Based Screen for Parkinson's Disease Identifies GW8510 as a Neuroprotective Agent. ACS Chem Neurosci 2016;7:857-63. https:\/\/doi.org\/10.1021\/acschemneuro.6b00076.","DOI":"10.1021\/acschemneuro.6b00076"},{"key":"#cr-split#-e_1_3_2_1_36_1.1","doi-asserted-by":"crossref","unstructured":"Chen P Wu J-N Shu Y Jiang H-G Zhao X-H Qian H Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction. Clin Sci 2018;132:1417-33. https:\/\/doi.org\/10.1042\/CS20180010. 10.1042\/CS20180010","DOI":"10.1042\/CS20180010"},{"key":"#cr-split#-e_1_3_2_1_36_1.2","doi-asserted-by":"crossref","unstructured":"Chen P Wu J-N Shu Y Jiang H-G Zhao X-H Qian H Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction. Clin Sci 2018;132:1417-33. https:\/\/doi.org\/10.1042\/CS20180010.","DOI":"10.1042\/CS20180010"},{"key":"#cr-split#-e_1_3_2_1_37_1.1","doi-asserted-by":"crossref","unstructured":"Xu T Wang Z Liu J Wang G Zhou D Du Y Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer. Front Oncol 2022;12:1-13. https:\/\/doi.org\/10.3389\/fonc.2022.820696. 10.3389\/fonc.2022.820696","DOI":"10.3389\/fonc.2022.820696"},{"key":"#cr-split#-e_1_3_2_1_37_1.2","doi-asserted-by":"crossref","unstructured":"Xu T Wang Z Liu J Wang G Zhou D Du Y Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer. Front Oncol 2022;12:1-13. https:\/\/doi.org\/10.3389\/fonc.2022.820696.","DOI":"10.3389\/fonc.2022.820696"},{"key":"#cr-split#-e_1_3_2_1_38_1.1","doi-asserted-by":"crossref","unstructured":"Malta TM Sokolov A Gentles AJ Burzykowski T Poisson L Weinstein JN Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 2018;173:338-354.e15. https:\/\/doi.org\/10.1016\/j.cell.2018.03.034. 10.1016\/j.cell.2018.03.034","DOI":"10.1016\/j.cell.2018.03.034"},{"key":"#cr-split#-e_1_3_2_1_38_1.2","doi-asserted-by":"crossref","unstructured":"Malta TM Sokolov A Gentles AJ Burzykowski T Poisson L Weinstein JN Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 2018;173:338-354.e15. https:\/\/doi.org\/10.1016\/j.cell.2018.03.034.","DOI":"10.1016\/j.cell.2018.03.034"},{"key":"#cr-split#-e_1_3_2_1_39_1.1","doi-asserted-by":"crossref","unstructured":"Ricardo S Vieira AF Gerhard R Leitao D Pinto R Cameselle-Teijeiro JF Breast cancer stem cell markers CD44 CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011;64:937-46. https:\/\/doi.org\/10.1136\/jcp.2011.090456. 10.1136\/jcp.2011.090456","DOI":"10.1136\/jcp.2011.090456"},{"key":"#cr-split#-e_1_3_2_1_39_1.2","doi-asserted-by":"crossref","unstructured":"Ricardo S Vieira AF Gerhard R Leitao D Pinto R Cameselle-Teijeiro JF Breast cancer stem cell markers CD44 CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011;64:937-46. https:\/\/doi.org\/10.1136\/jcp.2011.090456.","DOI":"10.1136\/jcp.2011.090456"},{"key":"#cr-split#-e_1_3_2_1_40_1.1","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN Stemmer SM Burris HA Yap Y-S Sonke GS Paluch-Shimon S Ribociclib as First-Line Therapy for HR-Positive Advanced Breast Cancer. N Engl J Med 2016;375:1738-48. https:\/\/doi.org\/10.1056\/NEJMoa1609709. 10.1056\/NEJMoa1609709","DOI":"10.1056\/NEJMoa1609709"},{"key":"#cr-split#-e_1_3_2_1_40_1.2","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN Stemmer SM Burris HA Yap Y-S Sonke GS Paluch-Shimon S Ribociclib as First-Line Therapy for HR-Positive Advanced Breast Cancer. N Engl J Med 2016;375:1738-48. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","DOI":"10.1056\/NEJMoa1609709"},{"key":"#cr-split#-e_1_3_2_1_41_1.1","doi-asserted-by":"crossref","unstructured":"Li Z-N Shu Y Chen C-G Li X-Q Li M-Y Zhao X-H Acquired tamoxifen resistance is surmounted by GW8510 through ribonucleotide reductase M2 downregulation-mediated autophagy induction. Biochem Biophys Res Commun 2020;528:554-60. https:\/\/doi.org\/10.1016\/j.bbrc.2020.05.149. 10.1016\/j.bbrc.2020.05.149","DOI":"10.1016\/j.bbrc.2020.05.149"},{"key":"#cr-split#-e_1_3_2_1_41_1.2","doi-asserted-by":"crossref","unstructured":"Li Z-N Shu Y Chen C-G Li X-Q Li M-Y Zhao X-H Acquired tamoxifen resistance is surmounted by GW8510 through ribonucleotide reductase M2 downregulation-mediated autophagy induction. Biochem Biophys Res Commun 2020;528:554-60. https:\/\/doi.org\/10.1016\/j.bbrc.2020.05.149.","DOI":"10.1016\/j.bbrc.2020.05.149"},{"key":"#cr-split#-e_1_3_2_1_42_1.1","doi-asserted-by":"crossref","unstructured":"Finn RS Martin M Rugo HS Jones S Im S-A Gelmon K Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016;375:1925-36. https:\/\/doi.org\/10.1056\/NEJMoa1607303. 10.1056\/NEJMoa1607303","DOI":"10.1056\/NEJMoa1607303"},{"key":"#cr-split#-e_1_3_2_1_42_1.2","doi-asserted-by":"crossref","unstructured":"Finn RS Martin M Rugo HS Jones S Im S-A Gelmon K Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016;375:1925-36. https:\/\/doi.org\/10.1056\/NEJMoa1607303.","DOI":"10.1056\/NEJMoa1607303"}],"event":{"name":"ICBBS 2022: 2022 11th International Conference on Bioinformatics and Biomedical Science","acronym":"ICBBS 2022","location":"Nanning China"},"container-title":["Proceedings of the 2022 11th International Conference on Bioinformatics and Biomedical Science"],"original-title":[],"link":[{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3571532.3571535","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dl.acm.org\/doi\/pdf\/10.1145\/3571532.3571535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T17:50:55Z","timestamp":1750182655000},"score":1,"resource":{"primary":{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3571532.3571535"}},"subtitle":["Small-Molecule Drugs Re-sensitizing TNBC to Tamoxifen"],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":81,"alternative-id":["10.1145\/3571532.3571535","10.1145\/3571532"],"URL":"https:\/\/doi.org\/10.1145\/3571532.3571535","relation":{},"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"2023-02-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}